Back
CCO Premium Access

Predictive capacity of the HFA-ICOS risk stratification scale for cardiovascular adverse events in patients treated with proteasome inhibitors

Session: Who is at risk of cardiovascular toxicity?
Topic: Stratification, Prevention and Monitoring
Speaker: Mr E. Pons-Fuster Lopez (Murcia, ES)
Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

Like

About the speaker

Mr Eduardo Pons-Fuster Lopez

Virgen de la Arrixaca University Clinical Hospital, Murcia (Spain)
0 follower

6 more presentations in this session

Cancer risks in heart failure patients: Insights from ischemic and non-ischemic cardiomyopathy

Speaker: Doctor S. Kim (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Unrecognized cardiovascular risks in young cervical cancer patients. Findings from the Rebuc study

Speaker: Doctor J. Hytting (Norrkoping, SE)

Access
Abstract
Slides
Like
Thumbnail

Three-year follow-up of anthracycline-induced cardiotoxicity risk in breast cancer patients using the HFA-ICOS score

Speaker: Doctor A. Amanova (Aktobe, KZ)

Access
Abstract
Slides
Like
Thumbnail

Framingham risk score associates with incident cancer and heart failure

Speaker: Doctor F. Van Den Berg (Rotterdam, NL)

Access
Abstract
Slides
Like
Thumbnail

Prognostic value of HFA-PEFF and H2FPEF scores in patients with advanced cancer: a prospective observational study

Speaker: Ms I. Baluta (Berlin, DE)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Who is at risk of cardiovascular toxicity?

Speakers: Mr E. Pons-Fuster Lopez, Doctor S. Kim, Doctor J. Hytting, Doctor A. Amanova, Doctor F. Van Den Berg...
Access
Like
Thumbnail

About the event

Image

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources